Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,955 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.
Wu R, Williams C, Zhou J, Schlackow I, Emberson J, Reith C, Keech A, Robson J, Armitage J, Gray A, Simes J, Baigent C, Mihaylova B; CTT Collaboration secretariat; Armitage J, Baigent C, Barnes E, Blackwell L, Collins R, Davies K, Emberson J, Fulcher J, Halls H, Herrington WG, Holland L, Keech A, Kirby A, Mihaylova B, O'Connell R, Preiss D, Reith C, Simes J, Wilson K; CTT Collaboration trialists: A to Z trial (phase Z); Blazing M, Braunwald E, Lemos J, Murphy S, Pedersen TR, Pfeffer M, White H, Wiviott S; AFCAPS/TEXCAPS (AirForce/Texas Coronary Atherosclerosis Prevention Study); Clearfield M, Downs JR, Gotto A Jr, Weis S; ALERT (Assessment of Lescol in Renal Transplantation); Fellström B, Holdaas H, Jardine A, Pedersen TR; ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial); Gordon D, Davis B, Furberg C, Grimm R, Pressel S, Probstfield JL, Rahman M, Simpson L; ALLIANCE (Aggressive Lipid-Lowering Initiation Abates New Cardiac Events); Koren M; ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial); Dahlöf B, Gupta A, Poulter N, Sever P, Wedel H; ASPEN (Atorvastatin Study for the Prevention of Coronary Heart Disease Endpoints in Non-Insulin Dependent Diabe… See abstract for full author list ➔ Wu R, et al. Among authors: shepherd j. Br J Gen Pract. 2024 Feb 19;74(740):e189-98. doi: 10.3399/BJGP.2023.0198. Online ahead of print. Br J Gen Pract. 2024. PMID: 38373851 Free PMC article.
A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics.
Ford I, Blauw GJ, Murphy MB, Shepherd J, Cobbe SM, Bollen EL, Buckley BM, Jukema JW, Hyland M, Gaw A, Lagaay AM, Perry IJ, Macfarlane P, Norrie J, Meinders AE, Sweeney BJ, Packard CJ, Westendorp RG, Twomey C, Stott DJ; The PROSPER Study Group. Ford I, et al. Among authors: shepherd j. Curr Control Trials Cardiovasc Med. 2002 May 20;3(1):8. doi: 10.1186/1468-6708-3-8. Curr Control Trials Cardiovasc Med. 2002. PMID: 12097148 Free PMC article.
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.
Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Sattar N, et al. Among authors: shepherd j. Circulation. 2003 Jul 29;108(4):414-9. doi: 10.1161/01.CIR.0000080897.52664.94. Epub 2003 Jul 14. Circulation. 2003. PMID: 12860911
Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M. Tonelli M, et al. Among authors: shepherd j. Circulation. 2004 Sep 21;110(12):1557-63. doi: 10.1161/01.CIR.0000143892.84582.60. Epub 2004 Sep 13. Circulation. 2004. PMID: 15364796 Review.
Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study.
Sattar N, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J; west of Scotland coronary prevention study. Sattar N, et al. Among authors: shepherd j. Diabetes. 2004 Nov;53(11):2855-60. doi: 10.2337/diabetes.53.11.2855. Diabetes. 2004. PMID: 15504965
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. LaRosa JC, et al. Among authors: shepherd j. N Engl J Med. 2005 Apr 7;352(14):1425-35. doi: 10.1056/NEJMoa050461. Epub 2005 Mar 8. N Engl J Med. 2005. PMID: 15755765 Free article. Clinical Trial.
Effect of pravastatin in people with diabetes and chronic kidney disease.
Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J, Isles C, Furberg C, West M, Craven T, Curhan G. Tonelli M, et al. Among authors: shepherd j. J Am Soc Nephrol. 2005 Dec;16(12):3748-54. doi: 10.1681/ASN.2005070779. Epub 2005 Oct 26. J Am Soc Nephrol. 2005. PMID: 16251235 Clinical Trial.
Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
Packard CJ, Ford I, Robertson M, Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER Study Group. Packard CJ, et al. Among authors: shepherd j. Circulation. 2005 Nov 15;112(20):3058-65. doi: 10.1161/CIRCULATIONAHA.104.526848. Epub 2005 Nov 7. Circulation. 2005. PMID: 16275871 Clinical Trial.
2,955 results